GSK3β inhibition also displayed anti-proliferative effects in other tumor entities, including leukemia, non-small cell lung cancer, melanoma, prostate, pancreatic, colon and renal cell carcinoma [73, 75, 78–83]. Here, GSK3B is linked to neoplasm.